Aptar Pharma and Dianosic Form Exclusive Partnership to Advance Intranasal Scaffold Drug Delivery Platform
Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, has announced an exclusive strategic partnership with French biotech innovator Dianosic. The collaboration focuses on the development and commercialization of the Active Resorbable Intranasal Scaffold (ARIS) technology platform, a breakthrough designed to improve treatment for patients suffering from Chronic Allergic Rhinitis (CAR) and Chronic Rhinosinusitis (CRS)—two conditions that affect millions worldwide.
Dianosic has been pioneering new approaches to intranasal therapeutic solutions, and its ARIS technology represents a significant advancement. The insert is bioresorbable, meaning it gradually dissolves in the body without the need for removal. Its primary purpose is to deliver drugs locally over extended periods, ensuring steady treatment where it is needed most while minimizing systemic side effects. By combining Aptar Pharma’s long-standing expertise in nasal drug delivery with Dianosic’s innovation, the partnership aims to transform the way these chronic conditions are treated.
Meeting an Unmet Clinical Need
Both Chronic Allergic Rhinitis and Chronic Rhinosinusitis pose considerable health burdens. They not only affect quality of life through symptoms such as nasal congestion, headaches, and breathing difficulties but also increase the risk of recurring infections and impact overall productivity. Existing therapies often require repeated dosing, invasive procedures, or demonstrate inconsistent results. The ARIS technology platform is being designed to directly address these challenges through its “insert and forget” drug delivery concept.
By placing the resorbable scaffold inside the nasal cavity, physicians can ensure that medication is released consistently and effectively for longer durations. For patients, this means fewer interventions, reduced reliance on strict dosing schedules, and greater adherence to prescribed treatment regimens. Ultimately, this can lead to improved outcomes, higher satisfaction, and enhanced overall quality of life.
Expanding into Nose-to-Brain (N2B) Delivery
While the initial focus is on treating CAR and CRS, the collaboration between Aptar Pharma and Dianosic will also explore broader applications—most notably Nose-to-Brain (N2B) drug delivery. This emerging therapeutic avenue is particularly relevant for addressing neuropsychiatric and neurodegenerative diseases, where direct delivery to the brain through nasal pathways could bypass traditional barriers and improve therapeutic effectiveness. The ARIS platform could, therefore, open new doors for innovative treatments targeting conditions such as Alzheimer’s disease, Parkinson’s disease, or depression.
Details of the Agreement
As part of the partnership, Aptar Pharma will invest in Dianosic and secure a role on its strategic committee. This will enable Aptar to actively contribute to guiding the development and commercialization of the ARIS technology. Furthermore, Aptar will promote the platform among its extensive customer base and explore opportunities to enhance the offering through its wide-ranging services.
The alliance brings together the complementary strengths of both companies. Dianosic contributes its proprietary design and clinical innovation, while Aptar provides global market reach, regulatory expertise, and integrated service capabilities. This combination is expected to accelerate the pathway of ARIS from research to clinical practice.
Leadership Perspectives
Commenting on the announcement, Alex Theodorakis, President Aptar Pharma Prescription, stated:
“This partnership with Dianosic expands our commitment to deliver innovative and patient-centric solutions by leveraging the potential of intranasal drug delivery. This transformative innovation represents a promising advancement in the management of Chronic Rhinitis and Sinusitis, and we are proud to support the ARIS journey to market.”
From Dianosic’s perspective, the partnership represents a milestone in its mission to broaden access to novel therapeutic solutions. Philippe Bastide, CEO and co-founder of Dianosic, added:
“We are thrilled to join forces with Aptar Pharma as it marks a major step towards making our drug-eluting resorbable Intranasal Scaffold platform accessible worldwide. This alliance supports our commitment to improving intranasal therapeutic options for patients with chronic nasal conditions.”
Theodorakis further emphasized that the collaboration reinforces Aptar Pharma’s leadership in nasal drug delivery:
“By leveraging Aptar Pharma’s expertise—alongside Noble’s capabilities in human factor studies and patient onboarding, and Aptar CSP’s active material sciences offering—this unique partnership with Dianosic aims at bringing to market a major value-added solution that enhances patient outcomes and delivers value to pharmaceutical partners.”
A Step Toward the Future of Drug Delivery
The exclusive partnership between Aptar Pharma and Dianosic underscores the growing importance of patient-centric, minimally invasive, and highly effective drug delivery technologies. With chronic nasal conditions remaining an area of significant unmet medical need, ARIS could redefine the standard of care by improving compliance, safety, and efficacy.
At the same time, the potential expansion into Nose-to-Brain delivery opens up new frontiers in addressing some of the most challenging neurological conditions. Together, Aptar Pharma and Dianosic are setting the stage for a new era of therapeutic possibilities, one where advanced intranasal platforms could deliver life-changing benefits for patients around the globe.
